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local control rate was 82% (95% CI: 76-91%). Complete 
toxicity data were available for 143 patients: 22% of them 
presented a G3+ acute toxicity, mainly as moist 
desquamation (n = 25) or diarrhoea (n = 10). Three 
patients presented a late grade 3 gastrointestinal toxicity 
(anal incontinence). No grade 4 acute or late toxicity was 
recorded. Patients treated with standard dynamic IMRT 
presented a significantly higher risk of acute grade 3 or 
more toxicity compared to those treated with VMAT or HT 
(38.5% vs 15.3%, p = 0.049). 
Conclusion  
Modern IMRT (VMAT or HT) with daily IGRT are effective 
and safe in treating AC patients, and should be considered 
the standard of care in this clinical setting. 
   
EP-1260  Helical Tomotherapy with Daily Image 
Guidance for Rectal Cancer patients 
B. De Bari1, A. Franzetti-Pellanda2, A. Saidi3, M. 
Biggiogero2, D. Hahnloser4, D. Wagner5, M. Montemurro5, 
J. Bourhis3, O. Ozsahin3 
1Hôpital Univ. Jean Minjoz, Radiation Oncology, 
Besançon, France 
2Clinica Luganese, Radiation Oncology, Lugano, 
Switzerland 
3Centre Hospitalier Universitaire Vaudois, Radiation 
Oncology, Lausanne, Switzerland 
4Centre Hospitalier Universitaire Vaudois, Surgery, 
Lausanne, Switzerland 
5Centre Hospitalier Universitaire Vaudois, Medical 
Oncology, Lausanne, Switzerland 
Purpose or Objective  
Helical Tomotherapy (HT) has only been recently 
introduced in the neoadjuvant treatment of locally 
advanced rectal cancer (LARC) patients (pts). Aim of this 
retrospective study is to report the results in terms of 
toxicity and local control of the largest population treated 
with neoadjuvant HT and chemotherapy (CRT) with daily 
image guidance (IGRT) followed by surgery.  
Material and Methods  
Data of 117 patients LARC pts treated in 2 Swiss 
Radiotherapy departments were collected and analyzed. 
Radiotherapy (RT) consisted of 45 Gy (1.8 Gy/fraction, 5 
days/week for 5 weeks) to the regional lymph nodes. 
Seventy pts also received a simultaneous-integrated boost 
(SIB) up to a total dose of 50 Gy to the tumor (2 
Gy/fraction, 5 days/week for 5 weeks). Chemotherapy 
consisted of capecitabine 850 mg/m2, twice daily, during 
the RT days. Following a mean interval after completion 
of CRT of 53 days (range, 13-142), all pts underwent 
surgery. Ninety-four patients (80.3%) received a low 
anterior resection (LAR), while 23 pts (19.7%) received an 
abdomino-perineal resection (APR). The resection status 
was classified as R0 in 107 patients, and R1 in 3 patients 
(not reported in 7 patients). 
  
Results  
The overall rate of G2 or more toxicity was 22% (22/117 
patients). Only 3 patients (2.5%) presented a G3 toxicity, 
as dermatitis (n = 1) or diarrhoea (n =2). None of the 
patients presented a G3 (or more) hematologic toxicity 
and/or G4 non-hematologic toxicity. After a median 
follow-up time of 23.3 months (range, 4.8 – 66.8), only 2 
pts (1.7%) presented a G3-4 late toxicity. The 3-year local 
control rate was 96.9% (95% confidence interval: 96.4 - 
97.3%).  
Conclusion  
CRT delivered with HT and daily IGRT shows excellent 
rates of local control with few acute toxicity.  Longer 
follow-up is needed to confirm these encouraging results.  
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Purpose or Objective  
Hypofractionated radiotherapy (HRT) preoperatively 
improves locoregional control (LRC) for resectable rectal 
cancer. In addition chemoradiotherapy alone provides 
complete response rates of 10-20%. For patients with 
localised disease, unfit for surgery or with metastatic 
disease, the efficacy of HRT regimens is less clear. We 
report a single centre study of HRT for non-surgically 
treated rectal cancer. 
Material and Methods  
We retrospectively reviewed all patients who received 
HRT between 2007 and 2015. Patients had histologically 
proven rectal cancer with localised or metastatic disease 
and were ineligible for surgery. The primary endpoint was 
overall survival (OS). Secondary endpoints were LRC, 
toxicity and objective symptom control. 
Results  
Between March 2007 and December 2015 48 patients 
received pelvic HRT for inoperable rectal cancer, 24 (50%) 
had locoregional disease. The median (range) age was 78 
years (44-93), 17 (35%) patients had performance status 3. 
Dose/fractionation delivered was 27 Gy/6# in 3 weeks, 31 
(64.6%) patients and 25 Gy/5# in 1 week, 12 patients, 
BED=88 Gy  for both regimens. Median (range) time from 
diagnosis to RT was 2.5 months (0.5-74 months). RT was 
delivered with a 3D conformal technique in 81% of cases. 
Two (4%) patients were re-treated with 8 Gy/1# and 16 
Gy/4#, after receiving 27 Gy/6# and 25Gy/5# 
respectively. At a median (range) follow up of 12 months 
(0.5-76), symptomatic improvement was documented in 
19 (39.5%) patients. All patients completed the prescribed 
regimen. Two (4%) patients died within 30 days of 
treatment. The 1 and 2 year survival rates for all patients 
were 45.8% and 16.7% respectively. Median (IQR) OS for 
patients with localised and metastatic disease were 13.4 
months (10.3-25) and 6.2 months (2.5-10.3) respectively. 
Of the 16 patients alive, 12 (75%) had localised disease 
with median (IQR) OS in this subgroup of 17.2 months 
(12.7-27.3). 
Conclusion  
Hypofractionated radiotherapy is efficacious and tolerable 
for patients with rectal cancer, ineligible for surgery. Long 
term control of localised disease control can be achieved 
in a minority. A prospective randomised study would 
further quantify the benefit of HRT for this poor prognosis 
rectal  cancer  subgroup. 
   
EP-1262  EBRT And HDRBT in Rectal Cancer Patients 
Who Are Medically Unfit Or Refuse Surgery 
C.L. Chiang1, V.W.Y. Lee2, C.S.Y. Yeung1, M.Y.P. Wong2, 
F.A.S. Lee1, S.Y. Tung1 
1Tuen Mun Hospital, Department of Clinical Oncology, 
Hong Kong, Hong Kong SAR China 
2Tuen Mun Hospital, Department of Medical Physics, 
Hong Kong, Hong Kong SAR China 
 
Purpose or Objective  
TME surgery is the mainstay of treatment for rectal 
cancer. For those who are either medically unfit or refuse 
the operation, radiotherapy is frequently recommended 
but rarely leads to cure. There is recently some evidence 
suggesting dose escalation by adding HDBRT after EBRT is 
a feasible and promising strategy for this population. 
However, optimal dose fractionation regime remains 
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unclear on how to balance to tumor control and toxicity. 
Herein we reported our early experience on using EBRT 
and HDBRT in rectal cancer patients who are either unfit 
or refuse surgery. 
Material and Methods  
During the period of Jan-2015 to Sep-2016, total 12 
consecutive patients treated with EBRT and HDRBT were 
analyzed; seven patients were because of medical 
inoperability, while five due to the refusal of surgery. 
Treatment consisted of EBRT with the regime (1.8Gy x 28, 
n=2; 5Gy x 5, n=4; 3Gy x 13, n=6) were at the discretion 
of physicians, followed by HDRBT boost given 8 weeks 
afterward. The starting dose level was 10Gy weekly x 1 
fraction, with escalation to maximum 3 fractions if acute 
toxicity was acceptable. The primary endpoint was acute 
toxicity. Secondary endpoints were tumor response, local 
control, and survival. Tumor responses were assessed 
based on endoscopy and MRI findings and classified as 
responding disease (CR + PR), static disease (SD) or 
progression (PD) 
 Results  
At the time of current analysis 9 patients were still alive 
and, median follow-up time was 13.6 months (range: 5.7–
19.2 months).  Median age 79 years (range: 70-88), ECOG 
2/3 (n=7/5), Charlson co-morbidity score <3 or ≥ 3 
(n=6/6); cT3/cT4 (n=11/1), Node positive/ negative 
(n=6/6), MRI predicted mesorectal fascia threatened 
(≤1mm) or not (n=7/5). Planned dose of HDRBT 10Gy x 1 / 
10Gy x 2/ 10Gy x 3 (n=6/3/3). One patient developed 
grade 3 toxicity (8.3%). Tumor response was observed in 
10 patients (83%). The local control rate at 1 year and 2 
years was 100% and 50% respectively. No patients received 
≥2 fractions HDBRT boost developed local progression. At 
1 year, the cancer specific survival was 81.5%, and the 
overall survival was 71.3%. Outcome related to dose level 
was  reported  in  table  1 
 
 
Conclusion  
In our early experience, the combination of EBRT and 
HDBRT achieves promising tumor response of 83% and 1-
year local control rate of 100% with acceptable acute 
toxicity. Longer follow-up is ongoing. Randomized trials 
are warranted to determine the optimal dose level of 
HDBRT.    
   
EP-1263  Short course radiotherapy, surgery &amp; 
chemotherapy for stage IV rectal cancer with liver 
metastasis. 
L. Díaz Gómez1, A. Seguro2, M. Macias1, E. Gonzalez1, I. 
Villanego1, L. De Ingunza1, V. Díaz1, L. Gutierrez1, M. 
Salas1, J. Jaén1 
1Hospital Universitario Puerta del Mar, Department of 
Radiation Oncology, Cadiz, Spain 
2Hospital de Jerez, Department of Medical Physics, Jerez 
de la Fra., Spain 
 
Purpose or Objective  
Resection of primary and liver lesions is the optimal 
management of Stage IV rectal cancer with liver 
metastases (Mets). The benefit of neoadjuvant in short 
course radiotherapy (5x5Gy) in terms of reduction of local 
recurrences and tumour downstaging have been well 
stablished with the publication of the Stockholm studies. 
Associating the benefit of both treatments by adding the 
effect of chemotherapy before or after liver surgery (some 
patients undergoing synchronous resection of the primary 
tumour and liver) and showing the data of our series of 
patients between 2014 and 2015 is the aim of our study 
Material and Methods  
16 patients were eligible for this study, 6 women and 10 
men in age 50-78 years at the time of treatment. All of 
them were MRI based stage with 3 patients cT3N1, 5 
cT4N2, 2 T4N1, 4 T3N2, 2 T2N2 and 1 to 3 liver Mets. We 
excluded of our study patients with more than 3 Mets 
because indication for surgery was ruled at diagnosis and 
only offered radiotherapy as palliation. Hypofractionated 
scheme radiotherapy was administered with a total dose 
of 25Gy and surgery was delayed for 7 days from the start 
of radiation therapy or at least 4 weeks as literature 
recommended. Chemotherapy used after surgery of the 
primary tumour was Folfox or Folfiri scheme with 3 or 6 
cycles depending number of liver Mets and patient 
characteristics.  
Results  
After radiotherapy complexion, 5 patients were into 
surgical resection in one week, and only 2 had synchronous 
surgery. Pathological findings showed 12 partial response, 
1 complete response and 2 stabilization of rectal tumour. 
Only 1 patient had a complete liver response after 
chemotherapy so he was excluded for liver surgery (Mets 
was not marked) At the time of liver surgery, 4 patients 
had lung and liver progression so they continued in second 
line chemotherapy. Until date, we´ve got 6 patients in 
follow-up without systemic therapy. The others 
progressed and are now under chemotherapy treatment. 
Only one patient died due to neoplastic disease.  
Conclusion  
Combined short course radiotherapy as neoadjuvant 
treatment in patients diagnosed of Stage IV rectal cancer 
with liver metastases follow of surgery and chemotherapy 
with curative intention can be a safe treatment option but 
must be demonstrated in future clinical trials. 
   
EP-1264  Metabolic response and change in CEA level 
in rectal cancer patients treated with neoadjuvant CRT 
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Song1, S. Ahn1, W. Chung1 
1Chonnam National University Hwasun Hospital, 
Radiation Oncology, Hwasun-eup, Korea Republic of 
 
Purpose or Objective  
We evaluated the significance of both metabolic response 
using 18F-fluorodeoxyglucose-positron emission 
tomography/computed tomography (PET/CT) and change 
of serum carcinoembryonic antigen (CEA) level before and 
after preoperative chemoradiotherapy (CRT) as 
prognosticators for survival in patients with for rectal 
cancer. 
Material and Methods  
We retrospectively analyzed T3-T4 or N+ rectal cancer 196 
patients who underwent preoperative CRT from October 
2008 to June 2013. All patients received a median of 
50.4 Gy in 28 fractions with 5-fluorouracil or capecitabine. 
The metabolic response was assessed by determining the 
maximal standardized uptake value (SUVmax), absolute 
difference (ΔSUVmax), and SUV reduction ratio (SRR) on 
pre- and post-CRT PET/CT scans. The serum CEA (pre-CRT 
and post-CRT), absolute difference (ΔCEA), CEA reduction 
ratio (CRR), and post-operative CEA (post-op CEA) were 
also determined. Multivariate analysis was performed 
using above parameters to determine any prognosticator 
for survival.   
Results  
Median follow-up period was 59 months. 5-year 
locoregional failure-free survival (LRFS), disease-free 
survival (DFS), and overall survival (OS) was 80.9 %, 66.0 
%, and 86.8 %, respectively. Median pre-CRT SUVmax, post-
CRT SUVmax, ΔSUVmax, and SRR were 13.5, 4.9, 11.5, and 
0.85, respectively. Median pre-CRT CEA, post-CRT CEA, 
ΔCEA, CRR, and post-op CEA were 4.42 ng/ml, 2.62 ng/ml, 
1.38 ng/ml, 0.34, and 1.55 ng/ml, respectively. On 
